US Stock MarketDetailed Quotes

NARI Inari Medical

Watchlist
  • 55.450
  • +1.040+1.91%
Close Dec 20 16:00 ET
  • 55.450
  • 0.0000.00%
Post 18:05 ET
3.25BMarket Cap-41.07P/E (TTM)

Inari Medical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Inari Medical Q3 2024 Earnings Date

Currency：USDOct 28, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
150.67M
153.39M
+2.72M
Beat Est.
+19.23%
+21.39%
+1.80%
EPS
-0.20
-0.31
-0.11
Miss Est.
-491.20%
-720.00%
-58.49%
Analyst Rating
Buy

Dec 18, 2024

Inari Medical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 9 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 168.403M--
--2024/Q4-- / 160.675M--
Oct 28, 20242024/Q3153.390M / 150.671M--
Jul 30, 20242024/Q2145.820M / 143.805M--
Apr 30, 20242024/Q1143.194M / 137.756M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 168.403M--
--2024/Q4-- / 160.675M--
Oct 28, 20242024/Q3153.390M / 150.671M--
Jul 30, 20242024/Q2145.820M / 143.805M--
Apr 30, 20242024/Q1143.194M / 137.756M--

Unlock Free Earnings Estimates

Inari Medical Earnings Reports

  • Inari Medical | 10-Q: Q3 2024 Earnings Report

    Oct 28 16:16 ET

  • Inari Medical | 8-K: Inari Medical Reports Third Quarter 2024 Financial Results

    Oct 28 16:10 ET

  • Inari Medical | 10-Q: Q2 2024 Earnings Report

    Jul 30 16:17 ET

  • Inari Medical | 8-K: Inari Medical Reports Second Quarter 2024 Financial Results

    Jul 30 16:12 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Ermenegildo Zegna NV
    ZGN
    +6.16%
    DexCom
    DXCM
    +5.57%
    New Fortress Energy
    NFE
    +5.37%
    Workday
    WDAY
    +2.33%
    eBay
    EBAY
    +1.66%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 18, 2024

    Buy

    • Buy

      58.33%

    • Hold

      41.67%

    • Sell

      0.00%

    Price Target

    No Data